Viable Mycobacterium avium subsp. paratuberculosis isolated from calf milk replacer by Grant, Irene R. et al.
Viable Mycobacterium avium subsp. paratuberculosis isolated from
calf milk replacer
Grant, I. R., Foddai, A. C. G., Tarrant, J. C., Kunkel, B., Hartmann, F. A., McGuirk, S., ... Collins, M. T. (2017).
Viable Mycobacterium avium subsp. paratuberculosis isolated from calf milk replacer. Journal of Dairy Science,
100(12). DOI: 10.3168/jds.2017-13154
Published in:
Journal of Dairy Science
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2017, The Authors. Published by FASS and Elsevier Inc. on behalf of the American Dairy Science Association®.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Nov. 2017
1 
 
 1 
VIABLE MAP ISOLATED FROM CALF MILK REPLACER 2 
 3 
 4 
Viable Mycobacterium avium ssp. paratuberculosis isolated from calf milk replacer 5 
 6 
Irene R. Grant,*1 Antonio C.G. Foddai,* James C. Tarrant,† Brenna Kunkel,† Faye A. 7 
Hartmann,‡ Sheila McGuirk,§ Chungyi Hansen,† Adel M. Talaat,† and Michael T. Collins† 8 
 9 
* Institute for Global Food Security, School of Biological Sciences, Queen’s University 10 
Belfast, Belfast, Northern Ireland, United Kingdom 11 
 12 
† Department of Pathobiological Sciences, and  13 
‡ Clinical Microbiology Laboratory, UW Veterinary Care, and 14 
§ Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-15 
Madison, Madison, Wisconsin, 53706 USA 16 
 17 
1Corresponding author: Dr Irene R. Grant, IGFS, School of Biological Sciences, Queen’s 18 
University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, Northern 19 
Ireland, UK.  E mail i.grant@qub.ac.uk   20 
2 
 
INTERPRETIVE SUMMARY 21 
 22 
Viable Mycobacterium avium ssp. paratuberculosis isolated from calf milk replacer. 23 
By Grant et al.  Calf milk replacer (CMR) is widely used for feeding calves to control 24 
infectious diseases, notably Johne’s disease. This practice assumes that CMR is free of 25 
viable Mycobacterium avium ssp. paratuberculosis (MAP). We tested 83 commercial CMR 26 
products obtained from US dairy farms. Seventeen (20.5%) CMR samples tested positive for 27 
viable MAP by a novel PMS-phage assay and 12 (14.5%) by PMS-culture. Seven (8.4%) 28 
tested positive for MAP DNA by IS900 qPCR. Conventional microbiological results were 29 
within the guidelines for whole milk powders. These findings highlight concerns about the 30 
ability of MAP to survive manufacture of dried milk-based products. 31 
 32 
ABSTRACT 33 
      When advising farmers on how to control Johne’s disease in an infected herd, one of the 34 
main recommendations is to avoid feeding waste milk to calves and instead feed calf milk 35 
replacer (CMR). This advice is based on the assumption that CMR is free of viable 36 
Mycobacterium avium ssp. paratuberculosis (MAP) cells; an assumption that has not 37 
previously been challenged. We tested commercial CMR products (n=83) obtained from 38 
dairy farms around the USA by the Peptide-mediated magnetic separation (PMS)-phage 39 
assay, PMS followed by liquid culture (PMS-culture), and direct IS900 qPCR. Conventional 40 
microbiological analyses for total mesophilic bacterial counts, coliforms, Salmonella, 41 
coagulase-negative staphylococci, streptococci, non-hemolytic Corynebacterium spp. and 42 
Bacillus spp. were also performed in order to assess the overall microbiological quality of the 43 
CMR. Twenty-six (31.3%) of the 83 CMR samples showed evidence of the presence of 44 
MAP. Seventeen (20.5%) tested positive for viable MAP by the PMS-phage assay, with 45 
plaque counts ranging from 6-1,212 PFU/50 mL reconstituted CMR (average 248.5 PFU/50 46 
mL). Twelve (14.5%) CMR samples tested positive for viable MAP by PMS-culture; isolates 47 
from all 12 of these samples were subsequently confirmed by whole genome sequencing to 48 
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be different cattle strains of MAP. Seven (8.4%) CMR samples tested positive for MAP DNA 49 
by IS900 qPCR. Four CMR samples tested positive by both PMS-based tests and five CMR 50 
samples tested positive by IS900 qPCR plus one or other of the PMS-based tests, but only 51 
one CMR sample tested positive by all three MAP detection tests applied. All conventional 52 
microbiology results were within current standards for whole milk powders. A significant 53 
association existed between higher total bacterial counts and presence of viable MAP 54 
indicated by either of the PMS-based assays (p=0.024). This represents the first published 55 
report of the isolation of viable MAP from CMR. Our findings raise concerns about the 56 
potential ability of MAP to survive manufacture of dried milk-based products.  57 
 58 
Keywords:  Mycobacterium avium ssp. paratuberculosis (MAP), milk replacer, calf health, 59 
Johne’s disease, infectious disease control  60 
INTRODUCTION 61 
 Milk replacer has been fed to calves since at least the 1950s, although formulations 62 
have changed over the years in terms of percentage fat and protein. Calf milk replacers 63 
(CMR) are generally made with by-products originating from milk processing industries, such 64 
as whole milk powder, skim milk powder, casein, whey and whey protein, although protein 65 
sources other than milk by-products such as soy products, dried egg, fish protein 66 
concentrates, single cell protein may also be used (FAO 2011, Bovine Alliance on 67 
Management and Nutrition 2014).  Most dairy calves in the United States of America (USA) 68 
are fed milk replacer prior to weaning for reasons of convenience, biosecurity and 69 
economics (Costello, 2012; Bovine Alliance on Management and Nutrition 2014). Calves are 70 
particularly susceptible to infectious diseases, and some infectious agents such as 71 
Mycobacterium avium ssp. paratuberculosis (MAP), the cause of Johne’s disease (JD), 72 
bovine viral diarrhea virus, bovine leukosis virus, Pasteurella multocida, Salmonella sp., and 73 
Mycoplasma bovis can be transmitted from cow to calf through feeding unpasteurised milk 74 
(Costello 2012). Feeding CMR, as an alternative to feeding waste unpasteurised milk or 75 
farm-pasteurized milk, is a common practice in the US. The latest statistics from the National 76 
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Herd Monitoring Scheme (NAHMS) indicate that 49.9% of all US dairy operations (of all 77 
sizes) fed some kind of CMR to pre-weaned heifers during 2014; 16.4% of operations fed 78 
non-medicated CMR and 37.6% fed medicated CMR (United States Department of 79 
Agriculture 2016).   80 
 As mentioned above, calves may be fed CMR to prevent diseases such as JD, caused 81 
by MAP which is shed in the milk and faeces of infected cows.  Transmission of MAP is 82 
considered to be an early event in a calf’s life, and there are recognised risk factors for 83 
transmission of MAP to calves within dairy herds (Doré et al. 2012). A focus of JD control 84 
programmes is on calf-related interventions as part of herd management plans. Avoid 85 
feeding waste milk and feed CMR instead is a key recommendation within JD control 86 
programmes worldwide (Doré et al. 2012, Garcia and Shalloo 2015, Pieper et al. 2015).  As 87 
stated by Cooper and Watson (2013), the assumption has always been that the risk of viable 88 
MAP organisms in commercial CMR powders is negligible because CMR is invariably 89 
pasteurised and often highly processed but is that really the case?  Seemingly, to date, no 90 
one has ever challenged that assumption. 91 
      Demonstrating the existence of viable MAP in processed milk or dairy products, such as 92 
pasteurized milk, cheeses, yoghurt, milk powders, and powdered infant formula, has proven 93 
difficult because, until recently, culture always necessitated inclusion of a chemical 94 
decontamination step to inactivate non-MAP contaminants; the latter is known to adversely 95 
impact the viability of some or all of the MAP cells present in milk, potentially leading to 96 
negative culture results (Dundee et al. 2001; Gao et al. 2005). However, detection methods 97 
for viable MAP in milk and dairy products have improved considerably over recent years with 98 
the advent of immunomagnetic separation (IMS, Grant et al. 1998; O’Brien et al. 2016) and 99 
subsequently peptide-mediated magnetic separation (PMS, Stratmann et al. 2002, 2006; 100 
Foddai et al. 2010; O’Brien et al. 2016), which permit selective capture, separation and 101 
concentration of whole MAP cells from a sample prior to culture or PCR, and novel 102 
mycobacteriophage-based methods of MAP detection (Stanley et al. 2007, Foddai et al. 103 
2010; Swift et al. 2013; Botsaris et al. 2016), which require the MAP cells to be viable to 104 
5 
 
obtain a positive result (plaques in a lawn of fast-growing Mycobacterium smegmatis). In 105 
particular, a method combining PMS and a phage amplification assay to detect MAP (PMS-106 
phage assay), developed and optimised by Foddai et al. (2009, 2011), and used in 107 
combination with an optimised milk sample preparation protocol (Foddai and Grant, 2015), is 108 
proving to be a very sensitive method of detecting viable MAP in cows’ milk. The optimised 109 
PMS-phage assay was recently reported to have a limit of detection 50% (LOD50) of ~1 MAP 110 
cell per 50 ml milk, making it a more sensitive detection method than existing MAP qPCR 111 
and conventional culture methods (Foddai and Grant, 2017).  112 
      As time passes, and the novel optimised PMS-phage assay is applied to test various 113 
milk and dairy products, new information on the presence and numbers of viable MAP in 114 
these foods is emerging (Foddai and Grant 2017). We previously reported the outcome of 115 
testing of powdered infant milk formula (PIF) by the PMS-phage assay (Grant et al. 2014). 116 
Of 68 PIF samples tested, 30 (44.1%) samples tested positive for viable MAP by the PMS-117 
phage assay, with viable MAP numbers ranging from 4–678 PFU/50 mL reconstituted PIF 118 
indicated by the plaque counts obtained. Since PIF and CMR are similar milk-based, 119 
powdered dairy products, probably with not dissimilar production processes, our viable MAP 120 
in PIF findings led us to query whether testing of CMR by the PMS-phage assay might also 121 
yield similar results with respect to the presence of viable MAP. Preliminary testing of a small 122 
number of CMR samples sourced in Wisconsin by the PMS–phage assay (carried out prior 123 
to the CMR testing reported here) found that 1 (12.5%) of 8 CMR samples tested positive for 124 
viable MAP. We hypothesized that viable MAP may be more widely prevalent in commercial 125 
powdered CMR products, so decided to carry out a larger study. The objectives of the study 126 
were: (1) to test commercial CMR products sourced from within the USA using standard 127 
culture methods, two PMS-based methods (PMS-phage assay and PMS plus liquid culture) 128 
and IS900 qPCR to detect the presence of viable MAP and MAP DNA, respectively, and (2) 129 
to assess the overall hygienic quality of the CMR samples by performing conventional 130 
microbiological analyses, in order to determine if the presence of any hygiene indicator 131 
microorganism might correlate with detection of viable MAP.  An optimised method for 132 
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detecting MAP in powdered dairy products has yet to be published, so during this study 133 
multiple methods, including several published and unpublished cultural and qPCR 134 
approaches (detailed below), were employed in the two CMR testing laboratories to 135 
maximise chances of detecting low numbers of viable MAP, if present, in the CMR samples. 136 
 137 
MATERIALS AND METHODS 138 
 139 
Acquisition of CMR Samples  140 
  141 
 CMR samples were acquired in two stages. In the first stage, 50 samples were acquired 142 
during the summer of 2014 from dairy farms in southern Wisconsin by author Tarrant. 143 
Hygiene precautions were taken to avoid on-farm contamination. Samples were collected 144 
with a sterile plastic scoop into sterile transport bags; with a separate sterile scoop being 145 
used for each sample. If a sealed bag of CMR was available on the farm that bag was used 146 
for sampling; the majority of the 50 Wisconsin sourced CMR samples were obtained from 147 
unopened bags of CMR (James Tarrant, University of Wisconsin-Madison, personal 148 
communication). Subsequently, during the spring of 2015, an additional 35 CMR samples 149 
were acquired from across the USA. For CMR collection outside Wisconsin, sample 150 
collection kits, including sterile scoops and bags, were mailed to veterinarians and veterinary 151 
students with detailed instructions about hygienic sampling technique and a request to use a 152 
sealed CMR bag if possible; all except two of the 35 CMR samples obtained in other US 153 
states were recorded as being from unopened bags. The 83 CMR samples ultimately tested 154 
originated from 15 US states and included 35 different brands of CMR representing six 155 
unique manufacturers.   156 
 157 
CMR Sample Reconstitution 158 
  159 
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      Unless otherwise stated, 6-9 g of each CMR sample (as indicated by the manufacturer’s 160 
label) was aseptically weighed into a sterile 50 ml centrifuge tube, reconstituted to 50 ml with 161 
pre-warmed (37oC) sterile distilled water, shaken thoroughly for several minutes to ensure 162 
resuspension of all powder, and then placed at 4oC overnight to fully rehydrate. Next day, 163 
the reconstituted CMR samples were removed from the fridge and allowed to equilibrate to 164 
room temperature for at least 1 h before being centrifuged at 3000 x g for 15 min. Each CMR 165 
pellet was then resuspended in 1-5 ml Phosphate buffered saline (pH 7.4) containing 0.05% 166 
Tween 20 (PBS-T), as appropriate depending on the size of pellet obtained, in order to 167 
obtain what was considered to be a suitable consistency for PMS.  The volume of PBS-T 168 
added was recorded so that a correction factor could be applied to plaque counts obtained 169 
when 1 ml of each CMR pellet sample was subjected to the PMS-phage assay. Finally, the 170 
reconstituted CMR pellet samples were ultrasonicated (pulse mode 37 kHz for 4 min in ice-171 
water) in an Ultrasonic bath (FB-11201, Fisher Scientific Ltd, Loughborough, UK) to break up 172 
any MAP clumps in the sample before PMS was performed.  Only one sample of each CMR 173 
was tested by each of the methods described below, so intra- or inter-laboratory variation for 174 
the methods employed was not evaluated during this study. 175 
 176 
PMS of MAP from reconstituted CMR  177 
 178 
      PMS was performed on 1 ml of each sample (prepared as indicated above) using 5 µl 179 
biotinylated-aMp3 peptide- and 5 µl biotinylated-aMptD peptide- coated MyOneTM 180 
Tosylactivated Dynabeads (Life Technologies, Paisley, Scotland, UK), prepared in-house as 181 
previously described (Foddai et al. 2010). A positive (1 ml of a 10-1 dilution of a broth culture 182 
of MAP B2) and negative (1 ml of 7H9 broth) control sample was included with each batch of 183 
15-20 CMR samples processed. Magnetic separation was carried out using a Dynal 184 
BeadRetriever (Life Technologies). MAP cell capture was carried out for 30 min at room 185 
temperature under continuous mixing, followed by two washes in 1 ml PBS-T, and final 186 
resuspension of the beads in 1 ml Middlebrook 7H9 broth containing 10% (v/v) OADC 187 
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supplement (7H9/OADC broth) and NOA antibiotic supplement (Abtek Biologicals Ltd., 188 
Liverpool, UK; final concentrations per litre: Nystatin 50,000 IU, Oxacillin 2 mg, Aztreonam 30 189 
mg).  This final 1 ml bead sample was split equally between the phage assay and culture, 190 
carried out as described below. The positive and negative PMS controls were also processed 191 
through the phage assay (PMS-phage assay) and culture (PMS-culture) along with each 192 
batch of test samples.   193 
 194 
PMS-Phage Assay  195 
 196 
      The PMS-phage assay and confirmatory plaque-PCR were carried out as follows: after 197 
PMS, 500 µl of each bead sample was transferred to a 11 ml flip-top vial (Capitol Vials, 198 
Auburn, AL, USA) containing 500 µl 7H9/OADC/4 mM CaCl2/NOA antibiotics (final CaCl2 199 
concentration in sample, 2 mM) before being incubated overnight at 37oC.  The phage assay 200 
was carried out as described by Foddai et al. (2009). Briefly, 100 µl D29 mycobacteriophage 201 
suspension (109 PFU/ml) was added to each bead sample, before incubation for 2 h at 37ºC. 202 
Then, in order to inactivate exogenous/non-adsorbed seed phage, 100 µl freshly prepared 203 
100 mM ferrous ammonium sulphate (FAS, Sigma-Aldrich, Poole, Dorset, UK) was added to 204 
each sample and allowed to incubate for 10 min at room temperature, with thorough 205 
vortexing of the sample after 5 min, before the addition of 5 ml 7H9/OADC/2 mM CaCl2/NOA 206 
broth. Samples were returned to the incubator at 37oC for a further 90 min before being 207 
plated with tempered (55oC) Middlebrook 7H9 agar containing 10% OADC (both Difco) and 208 
1 ml Mycobacterium smegmatis mc2 155 (108 CFU/ml). Plaques were counted following 209 
overnight incubation of plates at 37oC. Plaque counts obtained were expressed as plaque-210 
forming units (PFU)/50 ml reconstituted CMR; direct plaque counts were multiplied by a 211 
factor of 2 to take account of the fact that only half the bead sample (equivalent of 25 ml 212 
reconstituted CMR) was processed through the phage assay, and by a factor of 1, 3 or 5 to 213 
take account of the differing volumes of PBS-T originally added to resuspend the CMR 214 
pellets.   215 
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      Plaque-IS900 PCR, essentially as described by Swift et al. (2013), was carried out on 216 
DNA extracted from plaques in order to confirm that the DNA present was MAP DNA and not 217 
from some other Mycobacterium sp. Up to a maximum of 10 plaques were randomly selected 218 
from each PMS-phage assay positive sample plate to be excised for DNA extraction. The 219 
centre of each plaque was excised using a sterile loop and transferred to an Eppendorf tube. 220 
The DNA was extracted from the plaques using the Zymoclean™ Gel DNA Recovery kit 221 
(Cambridge Bioscience Ltd., Cambridge, UK), according to the manufacturer’s instructions. 222 
DNA was eluted from the Zymoclean columns using 20 µl elution buffer (supplied with kit). 223 
DNA was stored at -20°C until required for plaque-PCR. A protocol modified from Whittington 224 
et al. (1998) was used to target the IS900 insertion element. To 40 µl of master mix 225 
containing 1 X DreamTaq Green Buffer, 2.5 mM MgCl2, 200 µM of each dNTP, 1 U 226 
Fermentas DreamTaq DNA polymerase (Thermo Fisher Scientific, UK) and 250 ng of P90 227 
5’GAAGGGTGTTCGGGGCCGTCGCTTAGG’3 and P91 5’GGCGTTGAGGTCGATCGCCC 228 
ACGTGAC’3 primers, 10 µl of plaque DNA was added. The PCR cycling conditions were: 229 
94°C for 5 min, 37 cycles of 94°C for 30 sec, 62°C for 30 sec and 72°C for 1 min, final 230 
extension at 72°C for 4 min, and then sample cooled to 4°C. PCR products were visualised 231 
by 2% agarose gel electrophoresis. The expected IS900 PCR product size was 400 bp. 232 
 233 
PMS-Culture at Queen’s University Belfast (QUB) 234 
 235 
      PMS-culture and confirmation of suspect positive cultures was carried out as follows: 500 236 
µl of each bead suspension after PMS was inoculated into screw-capped glass test tubes 237 
containing 5 ml modified Middlebrook 7H9 liquid medium (Pozzato et al. 2011), consisting of 238 
(per 900 ml) 4.7 g Middlebrook 7H9 powder, 1.0 g casitone, 5 ml glycerol supplemented with 239 
10% v/v OADC supplement and PANTA plus antibiotic supplement (all Becton Dickinson) 240 
and mycobactin J (2 mg/l; Synbiotics Europe SAS, Lyon, France), but without the addition of 241 
16% egg yolk. The broth cultures were incubated at 37°C and absorbance at OD600nm was 242 
measured at time 0 and then from four weeks onwards every two weeks up to 16 weeks 243 
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using a Biowave CO8000 Density meter (Biochrom Ltd., Cambridge, UK). When an increase 244 
in OD600nm was observed for any broth culture, Ziehl-Neelsen (ZN) staining was employed to 245 
determine if acid-fast bacteria were present and, if so, IS900 PCR (Moss et al. 1992) was 246 
applied to confirm presence of MAP cells. Any primary PMS-culture suspected of containing 247 
viable MAP was sub-cultured to Dubos broth medium, prepared as described by Hammer et 248 
al. (2002) including the addition of 20% Newborn Calf Serum (Life Technologies), PACT 249 
antibiotics (Polymyxin B 50 IU/ml, Amphotericin B 5 µg/ml, Carbenicillin 25 µg/ml and 250 
Trimethoprim 2.5 µg/ml, all Sigma) and mycobactin J (2 mg/L, Synbiotics Europe SAS), and 251 
onto Herrold’s egg yolk medium (HEYM) containing 2 mg/L mycobactin J (prepared in-252 
house). Once again, OD600nm of broth cultures was measured periodically until an increase 253 
was observed, at which point IS900 PCR was applied to confirm the presence of MAP DNA. 254 
IS900 PCR was also applied to suspect colonies growing on HEYM plates to confirm their 255 
identity.  256 
 257 
PMS-Culture at University of Wisconsin-Madison (UW) 258 
 259 
      Reconstituted CMR was processed by PMS using the KingFisher Duo Prime Purification 260 
System (ThermoFisher Scientific, Fitchburg, WI) to concentrate MAP and then inoculated 261 
into MGIT ParaTB medium with 1.0 mL MGIT ParaTB supplement (which contains 262 
mycobactin J), 500 μL egg yolk emulsion and 200 μL MGIT PANTA added, and also onto 263 
HEY slants (all culture media and supplements from BD Diagnostic Systems, Sparks, 264 
Maryland).  For one set of MGIT ParaTB medium cultures the CMR was reconstituted as 265 
previously described (as per manufacturer label instructions; 6-9 gm/mL).  For the other 266 
cultures, all CMR samples were reconstituted at a standard 5g/50mL and allowed to 267 
rehydrate before testing commenced. 268 
     If suspicious colonies were seen on HEY or if the MGIT 960 instrument was signal-269 
positive, a five-target multiplex PCR was performed to establish if MAP was present (Shin, 270 
2010). The nature of the CMR material inoculated onto solid media tended to resemble 271 
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bacterial growth causing many cultures to be unnecessarily tested. In total 149 cultures 272 
(including both PMS-cultures and conventional cultures) were tested by multiplex PCR. 273 
 274 
Conventional Culture for MAP at UW 275 
 276 
      The sample processing method described by Botsaris et al. (2016) in a study of 277 
powdered infant formula was adapted and used with three different culture media.  CMR was 278 
first reconstituted in phosphate buffered saline pH 7.2 (PBS) at 1.0 g/5 mL, allowed to sit at 279 
20oC for 1 h, centrifuged at 2,500 x g for 15 min.  The pellet was resuspended in 0.75% 280 
hexadecylpyridinium chloride (HPC) and allowed to sit for 4 h at 20oC.  After centrifugation at 281 
2,500 x g for 15 min the pellet was resuspended in 1.0 mL sterile water.  Three media were 282 
inoculated: 200 μL onto HEY slants (BD Diagnostic Systems), 100 μL into MGIT ParaTB 283 
medium (BD Diagnostic Systems) supplemented with mycobactin J, egg yolk and PANTA, 284 
and 100 μL onto modified 7H10 agar plates supplemented with mycobactin-J, ADC and 285 
VAN.  Suspicious colonies on solid culture media (HEY or 7H10) and signal-positive MGIT 286 
cultures were tested by multiplex PCR, as described above for PMS-cultures, to establish if 287 
MAP had been isolated.  The nature of the CMR material inoculated onto solid media tended 288 
to resemble bacterial growth causing many cultures to be unnecessarily tested.  289 
 290 
IS900 qPCR at UW 291 
 292 
    Three method variations were used to test CMR samples for presence of MAP by IS900 293 
qPCR: 294 
Method 1 - For the first qPCR method, the CMR was reconstituted at 5 g/50 mL in sterile 295 
water, then held at 4oC for 18-24 h before centrifugation at 2,500 x g for 15 min. The pellet 296 
was resuspended in 3.0 mL sterile PBS containing 0.05% Tween 20. DNA was extracted 297 
from 1.0 mL of this suspension using the Tetracore Extraction System (Tetracore, Rockville, 298 
MD) using the 1.0 g protocol after agitation in the Benchmark BeadBlaster 24 (Benchmark 299 
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Scientific, Inc., Edison, NJ). From the 25 μL extraction product, 5 μL was used as template 300 
DNA for IS900 qPCR. 301 
Method 2 – For the second qPCR method, CMR was first reconstituted in PBS at 1.0 g/5 mL, 302 
allowed to sit at 20oC for 1 h, centrifuged at 2,500 x g for 15 min. The pellet was 303 
resuspended in 0.75% HPC and allowed to sit for 4 h at 20oC. After centrifugation at 2,500 x 304 
g for 15 min the pellet was resuspended in 1.0 mL sterile water. DNA was extracted from this 305 
suspension using the Tetracore Extraction System (Tetracore) using the 1.0 g protocol after 306 
agitation in the Benchmark BeadBlaster 24 (Benchmark Scientific). From the 25 μL 307 
extraction product, 5 μL was used as template DNA for IS900 qPCR. 308 
Method 3 - For the third qPCR method, the CMR was reconstituted at 1.0 g/9 mL, then held 309 
at 20oC for 1 h, then overnight at 4oC for 18-24 h. After centrifugation at 2,500 x g for 15 min, 310 
the pellet was reconstituted in 1.0 mL sterile Tris-EDTA (TE) buffer pH 8.0.  DNA was 311 
extracted from this suspension using the Tetracore Extraction System (Tetracore) using the 312 
1.0 g protocol after agitation in the Benchmark BeadBlaster 24 (Benchmark Scientific).  From 313 
the 25 μL extraction product, 5 μL was used as template DNA for IS900 qPCR. 314 
 315 
Conventional Microbiological Analyses at UW 316 
 317 
      All CMR samples were reconstituted as per manufacturer label instructions; 6-9 gm/50 318 
mL. The resulting milk sample was then tested by the same methods used to characterize 319 
the microbiological quality of bulk tank milk. Freshly reconstituted CMR was tested at the 320 
following four final dilutions: 1:50, 1:500, 1:5000, and 1:50000. Heat-stressed reconstituted 321 
milk replacer (37oC for 6 h) was tested at the same dilutions with the addition of two higher 322 
dilutions to anticipate the higher microbial counts: 1:100000 and 1:500000. Final dilutions 323 
were achieved by inoculating 0.2 mL of each primary dilution onto Trypticase soy agar (BAP) 324 
supplemented with 5% sheep blood (Remel Inc., Lenexa, KS) for determination of 325 
microorganism growth and total bacterial counts and eosin methylene blue (EMB) agar 326 
(Remel Inc., Lenexa, KS) to quantify lactose-fermenters (coliforms) and non-coliform, gram-327 
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negative bacteria. Culture plates were incubated at 36oC in 5% CO2 and examined for 328 
growth after 24, 48, and 36 hours of incubation. Each dilution was also inoculated onto XLT4 329 
agar (Remel Inc., Lenexa, KS), incubated in ambient air at 35oC and examined for growth of 330 
Salmonella after 24, 48, and 36 hours of incubation. In addition, enrichment culture for 331 
Salmonella was performed to increase sensitivity of Salmonella detection. Undiluted 332 
reconstituted CMR (0.2 mL) was inoculated into selenite and Rappaport-Vassiliadis 333 
enrichment broths (Remel Inc., Lenexa, KS). Enrichment broths were incubated for 18 hours 334 
in ambient air at 35oC and then subcultured onto XLT4 agar (Remel Inc., Lenexa, KS). 335 
Subcultures were incubated in ambient air at 35oC and examined for colonies resembling 336 
Salmonella after 24 and 48 hours of incubation.   337 
      Colony counts were recorded on the last day of incubation. All colony types were 338 
identified and classified into the following groups: coliform or non-coliform, gram-negative 339 
rods (lactose-positive or negative on EMB, respectively), streptococci (agalactiae or non-340 
agalactiae), staphylococci, (Staph. aureus or coagulase-negative staphylococci, CNS), 341 
Corynebacterium spp., Bacillus spp. or other microorganism using standard microbiological 342 
procedures (Hogan et al. 1999). Other microorganisms or species level identifications were 343 
performed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass 344 
spectrometry (Bruker Daltonics, Bremen, Germany). 345 
 346 
Genomic Analysis of MAP Isolates 347 
 348 
      When MAP isolates were successfully cultured at QUB, genomic DNA was extracted 349 
from cells grown in Dubos broth according to a method supplied by Dr Adel Talaat, University 350 
of Wisconsin-Madison (Hsu et al. 2011). Briefly, this involved heating at 80oC for 20 min to 351 
kill the mycobacterial cells, lysozyme and and proteinase K treatments to weaken the cell 352 
wall, and addition of 5M NaCl and CTAB/NaCl to lyse the MAP cells. This was followed by: 353 
(1) phenol/chloroform/isoamyl alcohol (24:24:1) extraction, (2) chloroform/isoamyl alcohol 354 
(24:1) extraction, (3) precipitation of DNA with isopropanol overnight, (4) washing with 70% 355 
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ethanol, and (5) resuspension of DNA pellet in 30 µl sterile molecular grade water. The purity 356 
and yield of DNA from each suspect MAP isolate was provisionally checked using a 357 
Biophotometer (Eppendorf, Germany) before the DNA samples were sent to the DNA 358 
Sequencing Facility, University of Wisconsin Biotechnology Center, Madison, WI.  All DNA 359 
samples were sequenced using Illumina Miseq platform and were run in paired-end with 250 360 
bp for each read.  Raw sequencing files were imported to CLCBio Genomic workbench 361 
version 8 for reference assembly using MAP K10 (NC_002944). Single nucleotide 362 
polymorphisms (SNPs), multiple nucleotide variant (MNV) and whole genome 363 
insertions/deletions were also analyzed using CLCBio software.  The criteria for variant 364 
calling included that a variant has ≥ 20 times sequence coverage where this variant is 365 
present in ≥ 50% of the sequence reads.  The consensus sequence of each sample was 366 
then extracted from CLCBio software and used to build a phylogenetic tree using 367 
HarvestTools (Treangen et al. 2014).  Finally, to distinguish MAP genotypes (Type I vs II or 368 
III), hsp65, gyrA and gyrB PCR followed by enzyme digestion were performed as detailed 369 
previously by Castellanos et al. (2007) and Ghosh et al. (2012).   370 
 371 
Statistical Analysis 372 
 373 
      The microbiological quality of CMR was compared for CMR samples that tested positive 374 
for viable MAP by phage assay or culture and those that did not, using the Mann-Whitney 375 
test with GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA); a 376 
difference with P-value  0.05 was considered significant at the 95% confidence level.  377 
 378 
 379 
RESULTS 380 
PMS-Phage Assay (QUB) 381 
 382 
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      Thirty-three (39.8%) of the 83 CMR samples tested by the PMS-phage assay yielded 383 
plaques, in which the presence of MAP DNA was detected by Plaque-PCR in 17 cases 384 
(Table 2); thus the presence of viable MAP was confirmed in 17 (20.5%) of the 83 CMR 385 
samples tested. Viable MAP numbers, indicated by plaque numbers in confirmed PMS-386 
phage assay positive samples, ranged from 6-1212 PFU/50 mL of reconstituted CMR (mean 387 
248.5 PFU/50 mL).   388 
 389 
PMS-Culture (QUB) or Conventional MAP Culture (UW) 390 
 391 
     At QUB, primary liquid cultures of 29 of the 83 CMR samples in modified Middlebrook 392 
7H9 medium (Pozzato et al. 2011) without egg yolk demonstrated an increase in OD600nm of 393 
0.1-0.7 units within the 16 week incubation period. When ZN stained, 18 of these cultures 394 
were observed to have acid-fast cells present, so were deemed suspect positive cultures. 395 
When the 18 suspect positive primary broth cultures were sub-cultured to Dubos medium 396 
and HEYM, 12 continued to show evidence of growth (an increase in OD600nm) in liquid 397 
culture or appearance of suspect colonies typical of MAP after 4-6 weeks on HEYM. All 12 398 
suspect cultures tested IS900 PCR so were provisionally identified as MAP. Ultimately, pure 399 
Dubos broth cultures of viable MAP were obtained from 12 (14.5%) of the 83 CMR samples 400 
originally tested. DNA was subsequently extracted from these pure broth cultures and sent 401 
to UW for whole genome sequencing.   402 
      At UW, CMR samples were cultured after PMS or conventional MAP culture protocols 403 
involving HPC decontamination in MGIT ParaTB medium supplemented with egg yolk.  404 
None of the UW cultures were positive for viable MAP. 405 
 406 
IS900 qPCR for MAP (UW) 407 
 408 
      Seven (8.4%) of the 83 CMR samples were IS900 qPCR-positive with Ct values of 28.3 409 
to 35.6, which translates to roughly 10-100 CFU of viable and non-viable MAP/g of CMR. 410 
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Five of the seven qPCR-positive samples (71%) were also positive by a test for viable MAP 411 
(PMS-phage assay or PMS-culture) at QUB (Figure 1).   412 
 413 
Inter-relationships between test results 414 
 415 
      Table 1 provides details of the PMS-phage assay, PMS-culture and qPCR results for 26 416 
(31.3%) of the 83 CMR samples which yielded a positive result by any of the three tests 417 
applied. Twenty-four (92.3%) of these CMR samples tested positive for the presence of 418 
viable MAP by either PMS-phage assay or PMS-culture, or both tests. MAP isolates were 419 
successfully cultured from 12 CMR samples overall. Only one CMR sample (KY-12), 420 
originating from a dairy farm in Kentucky, tested positive for MAP by all three tests applied 421 
(Table 1).  422 
 423 
Limited and Whole Genome Sequencing of Suspect MAP Isolates from CMR 424 
 425 
    Limited genotyping using hsp65, gyrA and gyrB indicated that the 12 suspected MAP 426 
isolates are from cattle source (Type II) and do not belong to types I or III.  These isolates 427 
were from three different US states, but the majority of isolates (N=10/12) were from 428 
Wisconsin.  We also performed whole genome sequence (WGS) analysis to further assay 429 
genomic diversity among isolates and begin to track the prevalence of MAP collected from 430 
CMR.  The WGS analysis confirmed that the 12 CMR isolates were MAP strains; as 431 
expected from the limited genotyping.  In fact, more than 99% of the sequencing reads were 432 
mapped to reference cattle strain, MAP-K10 (Table 3).  Identification of single nucleotide 433 
polymorphism (SNPs) among isolates and the standard laboratory strain (MAP-K10) 434 
revealed large numbers of SNPs that ranged between 151 and 267 SNPs per genome; a 435 
majority of which were shared among isolates from Wisconsin source CMR (Figure 2A).  436 
Interestingly, the percentages of non-synonymous SNPs were much higher than 437 
synonymous SNPs, and only a few SNPs were present in the intergenic regions (Figure 2B).  438 
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As expected, a phylogenetic tree of SNPs predicted from each genome (Figure 2C) showed 439 
a clear distinction from the MAP_S397 strain originally isolated from a sheep (Bannantine et 440 
al. 2012), but were closely related to K10 isolate from a cow (Wynne et al. 2010).  In 441 
addition, genomes from all CMR isolates clustered separately from genomes recently 442 
isolated from Elk circulating in California, USA (personal communications).  The sheer 443 
number of SNPs and their cluster pattern, different from traditional bovine strains used in 444 
most Johne’s testing laboratories, suggests a common source for these MAP isolates from 445 
CMRs collected in four different states.   446 
 447 
Conventional microbiological analyses (UW) 448 
 449 
      Standard measures of microbiological quality of CMR are summarized in Table 2. Total 450 
bacterial counts for the reconstituted 83 CMR samples ranged from 0-5.65 Log10 CFU/mL of 451 
reconstituted CMR (mean 2.66 ± 1.28 Log10 CFU/mL). Bacillus spp. represented the largest 452 
proportion (61%) of bacteria in most CMR (mean 2.33 ± 1.23 Log10 CFU/mL), followed by 453 
Streptococcus spp. (not agalactiae, 18%, mean 1.01 ± 1.44 Log10 CFU/mL) and coagulase-454 
negative Staphylococcus spp. (4%, mean 0.27 ± 0.91 Log10 CFU/mL) (Table 2). However, 455 
most striking was the large variation in microbiological quality among CMR samples tested. 456 
Eight samples had no bacterial growth detected at all. One CMR had a Log10 total count of 457 
3.18 per mL after reconstitution, all of which was due to Streptococcus spp. Another CMR 458 
sample had a Log10 total count of 5.2 per mL after reconstitution, all of which was due to 459 
Bacillus spp. No Salmonella spp. were detected in any CMR sampled, even after heat 460 
stressing the reconstituted CMR and using enrichment culture for Salmonella. Furthermore, 461 
no Streptococcus agalactiae or coagulase-positive Staphylococcus aureus were detected in 462 
any of the tested CMR. 463 
      When comparing microbiological results for viable MAP-positive CMR (PMS-phage 464 
assay or PMS-culture positive) to MAP-negative CMR, only total plate counts were 465 
significantly higher for MAP-positive CMR (p=0.024; Mann-Whitney test). 466 
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 467 
 468 
DISCUSSION 469 
      To our knowledge, this is only the second report of testing of commercial CMR products 470 
for the presence of viable MAP.  The first CMR study (Khol et al. 2017) reported negative 471 
results for 18 commercial CMR samples obtained from 15 different CMR manufacturers 472 
tested by qPCR and culture preceded by chemical decontamination.  In the present study 473 
three MAP detection approaches were taken – culture/PMS-culture, PMS-phage assay and 474 
IS900 qPCR – and viable MAP was detected in 24 (26%) of the 83 commercial CMR 475 
products tested, by either the PMS-phage assay or PMS-culture, or by both tests.  As this 476 
CMR testing was not as a result of randomized sampling this figure may not reflect the true 477 
viable MAP contamination rate for CMR more generally. Also, the CMR were collected on-478 
farm, rather than directly from CMR manufacturers, so the possibility of cross-contamination 479 
of some samples with MAP on potentially MAP-infected farms cannot completely be ruled 480 
out. Numbers of viable MAP indicated by the Plaque-PCR confirmed PMS-phage assay 481 
results ranged from 6-1,212 PFU/50 mL of reconstituted CMR (mean 248.5 PFU/50 mL). 482 
Plaques harvested from 16 of the 33 CMR samples yielding plaques were not confirmed to 483 
contain MAP DNA by Plaque-PCR; this may reflect insensitivity of the PCR when low levels 484 
of MAP DNA are present (e.g. DNA from a single MAP cell per plaque rather than a clump of 485 
MAP cells per plaque) and hence false negative Plaque-PCR results may have been 486 
obtained. However, the more likely explanation is that the virucide step did not achieve 487 
complete inactivation of the D29 phages added to the PMS sample at the start of the phage 488 
assay, and so some plaques observed were due to residual D29 phages and not 489 
mycobacterial cells bursting to release progeny D29 phages. This latter scenario is the main 490 
reason why the confirmatory Plaque-PCR step must be included.  MAP DNA was directly 491 
detected in just seven CMR samples by IS900 qPCR; five of which also tested PMS-culture 492 
or PMS-phage assay positive. It is unknown whether the mean number of viable MAP 493 
indicated by the PMS-phage assay for the MAP culture-positive CMR samples (248.5 494 
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PFU/50 mL reconstituted CMR), would represent sufficient inoculum to infect a calf, but the 495 
cumulative MAP dose from birth to weaning would not be insignificant, given the volume of 496 
CMR consumed by a calf over this period. 497 
      Suspected viable MAP isolates were cultured from 12 different CMR samples overall by 498 
liquid culture, with no chemical decontamination applied before culture.  From the outset of 499 
the study, we were very cognisant that the suggestion may be made that laboratory cross-500 
contamination could have contributed to any MAP positive cultures obtained, so the following 501 
practical measures were taken to avoid cross-contamination with viable MAP within the 502 
laboratory at QUB: (1) CMR samples were weighed out and/or reconstituted in a lab where 503 
MAP had never been worked with, and not in the CL2 laboratory where viable MAP may 504 
have been present; (2) Sterile, single-use disposable plasticware was routinely used for all 505 
manipulations and transfers in the CL2 laboratory; (3) Brand new screw-cap glass culture 506 
tubes were used for the CMR PMS-cultures and Dubos sub-cultures, and not recycled 507 
glassware that may have been previously used to culture MAP; and (4) CMR cultures were 508 
not opened until there was evidence of an increase in OD600nm, at which point a ZN stain was 509 
carried out to check for presence of acid-fast cells. If acid-fast positive, the culture was 510 
aseptically sub-cultured into Dubos broth, which, likewise, wasn’t opened until an increase in 511 
OD600nm was observed.   All 12 of the suspect MAP isolates were subsequently confirmed to 512 
be MAP by limited and whole genome sequencing; all were found to be of the cattle-type 513 
and all different from one another. The isolation of multiple different MAP strain types 514 
provides reassurance that the isolates obtained are not laboratory contaminants, but 515 
potentially have a common source that impacted herds in four different states out of the 15 516 
where farms were visited and CMR collected. The findings of this study suggest that the 517 
common source could be a MAP-contaminated CMR ingredient originating from MAP-518 
infected dairy cattle. 519 
      Culture of CMR was carried out using several different published methods. Conventional 520 
culture methods normally used for bovine fecal samples at UW or the method used to detect 521 
MAP in powdered infant formula by Botsaris et al. (2016), in the hands of very experienced 522 
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technicians in UW, failed to recover any viable MAP; these methods involved chemical 523 
decontamination prior to culture, which was similar to the approach taken by Khol et al. 524 
(2017) in their recent CMR study. Only a milk sample preparation and culture approach, 525 
optimised over recent years by researchers at QUB, was successful in isolating viable MAP 526 
from 12 CMR samples during this study. This approach included: (1) allowing time (overnight 527 
at 4oC following reconstitution of CMR) for complete rehydration of MAP cells present in 528 
CMR before testing commenced, (2) PMS to selectively capture MAP cells from CMR rather 529 
than exposing potentially injured MAP cells to a chemical decontamination treatment, (3) 530 
primary culture for up to 16 weeks in a modified Middlebrook 7H9 liquid medium (first 531 
described by Pozzato et al. 2011), which had casitone added but no egg yolk, to permit 532 
resuscitation of sub-lethally injured MAP cells, and (4) sub-culture of any primary cultures 533 
once evidence of MAP growth was observed into richer Dubos liquid medium (without egg 534 
yolk) and Herrold’s egg yolk medium to stimulate more copious growth of MAP.  It is difficult 535 
to explain the discrepant culture results at UW and QUB; we can only speculate on possible 536 
reasons. There were several distinct differences in terms of CMR sample preparation and 537 
culture media employed. Firstly, at QUB, once the CMR pellet was resuspended, the 538 
samples were subjected to an ultrasonication treatment to break up clumps of MAP cells. 539 
This may have had the effect of releasing viable or sub-lethally injured MAP cells from 540 
amongst predominantly dead cells (particularly after heat treatment) in clumps, giving them 541 
(greater) access to nutrients during primary culture in Pozzato medium. Secondly, no egg 542 
yolk was added to either the primary (Pozzato modified Middlebrook medium) or secondary 543 
(Dubos broth) culture media at QUB, whereas UW adds egg yolk routinely to liquid MGIT 544 
medium. The purpose of adding egg yolk to culture media used for MAP is still unclear, but 545 
neutralisation of the chemical decontaminant HPC seems to be a common reason 546 
(Whittington 2010). Whittington et al. (2013) subsequently suggested that egg yolk provides 547 
major carbon and energy sources as well as the surfactant lecithin. The question arises, are 548 
sub-lethally injured MAP cells likely to benefit from, or be adversely affected by, such a rich 549 
source of nutrients when trying to repair heat or dessication damage?  Thirdly, the primary 550 
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culture medium adopted by QUB contained added casitone (0.1%, 1 g/L) and a higher than 551 
normal amount of glycerol (0.5%, as per Pozzato et al. (2011) recipe, rather than 0.2%, 552 
which is the amount indicated by the manufacturer (Difco) of Middlebrook 7H9 broth). The 553 
additional ingredient, casitone, is a pancreatic enzymatic digest of casein (milk protein) that 554 
contains a particularly high content of amino acids and peptides of varying sizes making it a 555 
nutritious hydrolysate (BD Biosciences 2017). Glycerol, or alternatively Tween 80, both of 556 
which are surfactants, can be added to Middlebrook 7H9 broth to reduce clumping of 557 
mycobacterial cells during culture; although, as stated above, 0.2% is the recommended 558 
glycerol concentration for this purpose. Glycerol would also represent a carbon source; a 559 
very old publication (Sattler and Youmans 1948) relating to the effects of glycerol on tubercle 560 
bacilli (M. tuberculosis) reported that glucose and glycerol increased their total amount of 561 
growth but not their initial rate of multiplication. In light of the MAP isolation success at QUB 562 
during this study, we would like to suggest that the optimal culture approach for isolation of 563 
MAP from powdered milk products could be liquid culture in the modified 7H9 medium of 564 
Pozzato et al. (2011), with PANTA but without egg yolk, following PMS to capture MAP cells 565 
from reconstituted CMR that has had time to completely rehydrate before testing 566 
commences. Chemical decontamination with HPC should definitely be avoided because of 567 
its known deleterious effects on the viability of MAP cells (Dundee et al. 2001, Gao et al. 568 
2005), and, therefore, the distinct possibility that false negative results will be obtained when 569 
testing dairy products containing low numbers of MAP. The latter, plus the fact that solid 570 
Herrold’s egg yolk medium rather than a liquid culture medium was used by Khol et al. 571 
(2017), could explain their negative culture findings for CMR.  Liquid culture is likely to be 572 
more conducive to recovery of stressed MAP cells than culture on solid agar media simply 573 
because the bacterial cells are able to access water and nutrients more readily.  574 
      When CMR samples were being sourced for this study, every effort was made to 575 
hygienically collect CMR on the farms visited and to collect CMR samples from unopened 576 
bags. The vast majority of the 26 CMR samples that tested MAP positive (Table 1) were 577 
sampled from unopened bags; just one of the positive samples (OH-013) is known to be 578 
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from an already opened bag of CMR. However, the possibility of contamination of CMR 579 
samples by manure on the farm during collection cannot be totally ruled out because of the 580 
difficulties in maintaining hygienic practices in a dirty sampling environment, despite the best 581 
efforts of sampling personnel involved. Generally, all of the conventional measures of 582 
microbiological quality applied to the CMR samples were within normal limits for whole milk 583 
powders as set down in United States Department of Agriculture-Agricultural Marketing 584 
Service Standards for milk and dairy products. These Standards stipulate total bacterial 585 
counts <500,000 CFU/g and coliform counts  10 CFU/g for dry whole milk powders (USDA-586 
AMS 2001). The only statistically significant association between the conventional 587 
microbiological analyses and viable MAP presence in CMR was in relation to total plate 588 
counts, which were found to be significantly higher for viable MAP-positive CMR than for 589 
MAP-negative CMR (p=0.024; Mann-Whitney test).  In our opinion, this association does not 590 
necessarily indicate greater contamination of the CMR with MAP on-farm, but rather could 591 
reflect the possibility that the raw milk used to produce CMR ingredients contained higher 592 
numbers of MAP that have been able to survive heat treatments applied during milk powder 593 
production.   594 
  595 
CONCLUSIONS 596 
 597 
      Viable MAP were detected in 24 (28.9%) of 83 CMR samples collected at US dairy 598 
farms; 12 were positive by PMS-culture, 17 by PMS-phage assay, and 5 samples were 599 
positive by both of these tests. A further two CMR samples tested positive for MAP DNA by 600 
IS900 qPCR. The presence of viable MAP in CMR was significantly associated with higher 601 
total bacterial counts, but with none of the other microbiological parameters. This is the first 602 
report of viable MAP in CMR, but not the first report of viable MAP in powdered milk 603 
products. The source of the viable MAP detected cannot be verified; whether pre- or post-604 
processing contamination. It is unknown if the quantity of MAP detected in CMR would be 605 
sufficient to cause infection of a calf. However, the prospect that MAP has survived the 606 
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manufacture of dried milk and whey-based products which are destined for consumption by 607 
food animals could have far reaching potential consequences; further testing of CMR 608 
collected directly at manufacturing sites using the PMS and liquid culture approach 609 
described above is warranted to verify our findings. The broader food safety implications of 610 
detecting viable MAP in this type of dried dairy product are not insignificant given that 611 
powdered infant formulae is consumed by young babies with immature immune systems.   612 
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Table 1.  Detailed PMS-phage assay, PMS-culture and direct IS900 qPCR results, and US 757 
state of origin information, for the 26 calf milk replacer (CMR) samples that tested positive by 758 
one or more of the MAP detection tests. 759 
CMR code 
(US state of origin-
sequence no.) 
PMS-phage assay 
PMS-culture  Direct  IS900 qPCR No. of plaques per 50 ml reconstituted CMR 
Plaque IS900 
PCR result 
WI-001 696 + - - 
WI-002 822 + - - 
WI-003 150 + - - 
WI-004 38 + + - 
WI-006 0 - + - 
WI-007 0 - + - 
WI-012 1720 - + + 
WI-013 1212 + (weak) + - 
WI-014 0 - + - 
WI-025 0 - + - 
WI-038 30 + - - 
WI-048 0 - + - 
WI-050 80 + (weak) + - 
TX-004 12 - - + 
KY-006 12 + - - 
UT-010 30 + - - 
KY-012 40 + + + 
OH-0131 1020 + - + 
NY-015 6 + - + 
KY-016 0 - + - 
GA-017 10 + - + 
KY-020 0 - - + 
IA-026 6 + - - 
NY-027 6 + - - 
WA-031 30 + (weak) + - 
NY-032 36 + - - 
Total no. CMR samples positive 17 123 7 
Average no. MAP (PFU/50 ml reconstituted 
CMR) in test positive samples 2 248.5 116.7 153.7 
1 Only CMR sample known to have been collected from an already opened bag of CMR.  760 
2 The average number of plaque-forming units (PFU)/50mL reconstituted CMR for PMS-761 
culture and qPCR positive samples were calculated based on the number of PFU indicated 762 
by the corresponding PMS-phage assay result for those samples; a negative PMS-phage 763 
assay result equated to 0 PFU/50 ml reconstituted CMR. 764 
3 All 12 isolates from culture-positive CMR samples were subjected to whole genome 765 
sequencing with the results shown in Fig. 2. 766 
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Table 2.  Results of microbiological analyses performed on the 83 calf milk replacer (CMR) 767 
products that were tested for the presence of viable MAP in order to elucidate numbers and 768 
types of bacteria present. Data presented are minimum, maximum and mean counts (Log10 769 
CFU/mL) obtained for each analysis following reconstitution of the CMR samples according 770 
to manufacturer’s instructions in sterile water. 771 
 772 
 Total 
Plate 
Count 
Gram negative bacteria  Gram positive bacteria* 
Coliforms Non-
coliforms 
 Strep CNS Coryne Bac 
Min. count 0.00 0.00 0.00  0.00 0.00 0.00 0.00 
Max. count 5.65 2.19 2.74  5.23 5.29 2.65 5.65 
Mean count 2.66 0.03 0.03  1.01 0.27 0.15 2.33 
SD 1.28 0.24 0.30  1.44 0.91 0.54 1.23 
*Strep, Streptococcus spp.; CNS, coagulase-negative staphylococci; Coryne, 773 
Corynebacterium spp.; Bac, Bacillus spp.  774 
775 
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Table 3.  Reference assembly summaries for 12 MAP isolates cultured from CMR during 776 
this study, and for four unrelated Elk MAP isolates.  First two letters of MAP isolate no. relate 777 
to US state where CMR sample was collected. 778 
MAP Isolate 
No. Total reads 
% Mapped 
Reads 
Average 
coverage 
No. of Single 
Nucleotide 
Polymorphisms 
(SNPs) 
WI-004 2596628 99.35 125.66 204 
WI-006 2632574 99.44 127.26 251 
WI-007 3050230 93.39 139.58 261 
WI-012 2617894 99.57 127.73 213 
WI-013 2990666 96.31 148.78 256 
WI-014 2407414 99.28 123.36 259 
WI-025 2535896 99.42 130.18 151 
WI-048 2288424 99.47 117.59 260 
WI-050 2612622 99.04 133.55 257 
KY-012 2966692 99.41 152.25 267 
KY-016 2594488 98.87 132.39 257 
WA-031 2493940 99.2 127.79 252 
Elk8B-1 2121874 99.38 100.83 142 
Elk8B-2 2683464 99.41 130.28 150 
Elk10A 2628938 99.61 128.71 146 
Elk10B 2746440 99.59 134.07 148 
 779 
 780 
  781 
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Figure captions 782 
 783 
Figure 1   784 
Venn diagram showing the interrelationships between results obtained by the PMS-phage 785 
assay, PMS-culture and direct IS900 qPCR for 83 calf milk replacer (CMR) samples.  786 
Overlapping areas indicate numbers of CMR samples positive by more than one of the MAP 787 
detection tests.   788 
 789 
Figure 2   790 
Phylogenetic analysis of 12 MAP isolates obtained from different calf milk replacer (CMR) 791 
products and the MAP K10 reference strain. The first two letters of each strain ID indicate 792 
the US state of origin of the CMR sample from which the isolate was obtained.  A) Venn 793 
diagrams displaying the number of common and different single nucleotide polymorphisms 794 
(SNPs) found among representative CMR isolates.  B) The percentages of synonymous 795 
(SSNPs), non-synonymous (nSNPs) and intergenic SNPs found in the genomes of the 12 796 
CMR isolates.  C) A phylogenetic tree of the genomes of 12 CMR isolates with the presence 797 
of other genomes including the standard bovine type (K-10), an ovine type (S397), and four 798 
Elk isolates of US origin.  Concatenated SNPs were used from all isolates to build a rooted 799 
Neighbor-joining tree using MAP-S397 genome as an out group.  The percentages of a 1000 800 
bootstrap replicates are shown on the dendogram.  801 
 802 
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